Dualitas
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $65M
Overview
Creating bispecific antibody therapies for oncology and immunology.
OncologyImmunology
Technology Platform
Proprietary bispecific antibody engineering platform focused on novel formats for immune cell engagement and dual-target modulation.
Funding History
1Total raised:$65M
Series A$65M
Opportunities
Potential to create best-in-class therapies by improving on the efficacy of monospecific antibodies in validated pathways.
Risk Factors
Intense competition and high technical hurdles in demonstrating clinical benefit and manufacturability of novel bispecific formats.
Competitive Landscape
Enters a highly competitive bispecific antibody field with numerous large biopharma and biotech companies.